A 194% Payout Ratio?

This company is trending in the wrong direction... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

AN OXFORD CLUB PUBLICATION

View in browser SPONSORED The Most Important AI Stock NOBODY Is Talking About It's the inventor of the world's first AI-designed drugs to reach clinical trials. And Big Pharma is lining up to work with them. They have collaborations worth up to $6.8 billion with Merck, Sanofi, Bristol Myers Squibb and more. Yet the company now trades for less than $10. See why the man who bought Apple in '96... Netflix in 2005... and Amazon in 2005... says this is the #1 AI stock for the next 10 years. Editor's Note: We're doing something a little different for this week's Safety Net. We normally wouldn't cover the same stock in The Value Meter and Safety Net within a week. But several of you asked us to evaluate Pfizer in both columns, so we thought it'd be valuable to take a look at it from both a value angle and a dividend angle. Remember, a stock's valuation and its dividend safety can be very different. Be sure to gather as much information as possible before buying a stock, and always consider which strategies are the best fit for you and your investing goals. - Rachel Gearhart, Publisher SAFETY NET Beware This Dangerous 6.3% Yielder John Oravec, Research Analyst, The Oxford Club COVID-19 put a lot of companies in the spotlight. Cruise companies like Carnival (NYSE: CCL) found themselves without any customers... And tech companies like Zoom Video Communications (Nasdaq: ZM) and Teladoc Health (NYSE: TDOC) found a sudden windfall of cash... But no company shined more than the vaccine makers Moderna (Nasdaq: MRNA) and Pfizer (NYSE: PFE). Back in 2021, Marc covered Pfizer and gave it a fantastic dividend safety rating of "A." But that was back then. This is now. As Director of Trading Anthony Summers showed you on Friday, Pfizer's stock may no longer be the golden child it used to be for your portfolio. Perhaps it's a different story when it comes to Pfizer's dividend, though. The company currently pays a quarterly dividend of $0.42, which equates to a very nice annual yield of 6.3%. Is the dividend still as trustworthy as it was in 2021? Let's dive into the numbers... SPONSORED Legendary Investor Paul Tudor Jones Predicts "Violent Death" for Putin   Source: Wikimedia Commons   Few people know this, but Putin just made the single biggest mistake of his life. It's not invading Ukraine... but it could have a profound effect on world markets. A market expert breaks down the opportunity here. Pfizer's stock had a particularly awful 2023, losing nearly half of its value. View larger image   Much of that decline was fueled by a massive drop in revenue. And where there's a drop in revenue, we'll almost certainly see a drop in free cash flow. In 2022, Pfizer's free cash flow was $26 billion. Fast-forward to 2023, and we see that it fell to only $4.8 billion. View larger image   That's an 81.6% drop in just one year. And it has me seeing red flags all over. On top of that, the decline in free cash flow resulted in a 194% payout ratio for the company. That's well above our 75% threshold. In addition to seeing red flags, I'm now hearing sirens in the distance for the company's dividend... Finish Reading and Get My Grade Here BUILD AND PROTECT YOUR WEALTH Here are Three Steps You Need to Take to Protect and Grow Your Money When America Is Threatened With Mass Unemployment. Watch This Before AI Goes Supernova. What Warren Buffett Told Shareholders Get Marc's Top 5 Dividend Stocks (FREE PICKS) I Was Terrible at Trading (Until I Learned This) MORE FROM WEALTHY RETIREMENT Is Pfizer a "Buy" After Crashing Back to Earth? Brookfield Renewable Corp.: Can It Afford Its 5.5% Yield? China's Pain Could Be the Rest of the World's Gain A Brief History of the Markets Facebook LinkedIn Email Share Push Alert SPONSORED He owns... Amazon... ↑ 6,300% Netflix... ↑ 20,400% Apple... ↑ 94,000%. Now he's unveiling the... "Next Great American Super Stock." More Here You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2024 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 877.808.9795 | International: +1.443.353.4621 Oxfordclub.com Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.